1.Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evidence-Based Complementary and Alternative Medicine. 2011;2011.
2.Serviddio G, Bellanti F, Stanca E, Lunetti P, Blonda M, Tamborra R, et al. Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis. Free Radical Biology and Medicine. 2014;73:117–26.
3.Wu J-W, Lin L-C, Hung S-C, Lin C-H, Chi C-W, Tsai T-H. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug metabolism and disposition. 2008;36(3):589–96.
4.Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-κB and signal transducers and activators of transcription 3. Cancer Prevention Research. 2009;2(1):74–83.
5.Dastpeyman M, Motamed N, Azadmanesh K, Mostafavi E, Kia V, Jahanian-Najafabadi A, et al. Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB–231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf–1 and D4GDI. Medical Oncology. 2012;29(4):2512–8.
6.Kauntz H, Bousserouel S, Gosse F, Marescaux J, Raul F. Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis. International journal of oncology. 2012;41(3):849–54.
7.Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of β-catenin-dependent signaling. Neoplasia. 2010;12(5):415–24.
8.Varghese L, Agarwal C, Tyagi A, Singh RP, Agarwal R. Silibinin efficacy against human hepatocellular carcinoma. Clinical cancer research. 2005;11(23):8441–8.
9.Lee M-H, Huang Z, Kim DJ, Kim S-H, Kim MO, Lee S-Y, et al. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prevention Research. 2013;6(5):455–65.
10.Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clinical Cancer Research. 2008;14(1):300–8.
11.Deep G, Gangar SC, Rajamanickam S, Raina K, Gu M, Agarwal C, et al. Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. PloS one. 2012;7(4):e34630.
12.Liang L, Li L, Zeng J, Gao Y, Chen Y-L, Wang Z-Q, et al. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP–9 signaling pathway. Oncology reports. 2012;28(3):999–1005.
13.Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clinical Cancer Research. 2008;14(23):7773–80.
14.Deep G, Kumar R, Nambiar DK, Jain AK, Ramteke AM, Serkova NJ, et al. Silibinin inhibits hypoxia‐induced HIF‐1α‐mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics. Molecular carcinogenesis. 2017;56(3):833–48.
15.Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer research. 2008;68(6):2043–50.
16.Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vascular health and risk management. 2006;2(3):213.
17.Tiwari P, Mishra K. Silibinin in cancer therapy: A promising prospect. Cancer Res Front. 2015;1(3):303–18.
18.Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 1999;20(11):2101–8.
19.Wing Ying Cheung C, Gibbons N, Wayne Johnson D, Lawrence Nicol D. Silibinin-a promising new treatment for cancer. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2010;10(3):186–95.
20.Mahmud A, Xiong X-B, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. Journal of Drug Targeting. 2007;15(9):553–84.
21.Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature reviews cancer. 2005;5(3):161.
22.Jain K. Nanotechnology-based drug delivery for cancer. Technology in cancer research & treatment. 2005;4(4):407–16.
23.Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in pharmacological sciences. 2009;30(11):592–9.
24.Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems. Clinical pharmacokinetics. 2008;47(10):619–34.
25.Millimouno FM, Dong J, Yang L, Li J, Li X. Targeting apoptosis pathways in cancer and perspectives with natural compounds from mother nature. Cancer prevention research. 2014;7(11):1081–107.
26.Flaig TW, Gustafson DL, Su L-J, Zirrolli JA, Crighton F, Harrison GS, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational new drugs. 2007;25(2):139–46.
27.Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radical Biology and Medicine. 2012;52(9):1658–65.
28.Amawi H, Ashby CR, Tiwari AK. Cancer chemoprevention through dietary flavonoids: what’s limiting? Chinese journal of cancer. 2017;36(1):50.
29.Tatiraju DV, Bagade VB, Karambelkar PJ, Jadhav VM, Kadam V. Natural bioenhancers: An overview. J Pharmacogn Phytochem. 2013;2(3):55–60.
30.Macedo AS, Quelhas S, Silva AM, Souto EB. Nanoemulsions for delivery of flavonoids: formulation and in vitro release of rutin as model drug. Pharmaceutical development and technology. 2014;19(6):677–80.
31.Siddiqui MR, AlOthman ZA, Rahman N. Analytical techniques in pharmaceutical analysis: A review. Arabian Journal of chemistry. 2017;10:S1409-S21.
32.Hassan B. HPLC uses and importance in the Pharmaceutical Analysis and industrial field. Pharmaceut Anal Acta. 2012;3(9).
33.Mowafy HA, Alanazi FK, El Maghraby GM. Development and validation of an HPLC–UV method for the quantification of carbamazepine in rabbit plasma. Saudi Pharmaceutical Journal. 2012;20(1):29–34.